Key result
HCM affects ~400,000 individuals in Brazil and exhibits significant phenotypic and clinical heterogeneity.
Why the study?
Hypertrophic cardiomyopathy is the most prevalent genetically determined heart disease and remains a diagnostic and prognostic challenge.
The paper provides an overview of hypertrophic cardiomyopathy in Brazil, emphasizing its high prevalence and clinical heterogeneity.
Supports increased HCM recognition in Brazil; leaves open optimal strategies for its phenotypic heterogeneity.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Guazzelli et al. (2025) conducted a review in Hypertrophic cardiomyopathy (HCM). Hypertrophic cardiomyopathy is a highly prevalent genetic heart disease affecting an estimated 400,000 individuals in Brazil, characterized by significant phenotypic and clinical heterogeneity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: